Coagulation factor VIIa Other names: Proconvertin Eptacog alfa

Therapeutic indications

Coagulation factor VIIa is indicated for:

Bleeding in congenital haemophilia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Recombinant coagulation factor VIIa is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX >5 Bethesda Units (BU) and in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bleeding in acquired haemophilia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Recombinant coagulation factor VIIa is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in patients with acquired haemophilia.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bleeding in congenital FVII deficiency

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Recombinant coagulation factor VIIa is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in patients with congenital FVII deficiency.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bleeding in Glanzmann's thrombasthenia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Recombinant coagulation factor VIIa is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.